Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform

We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Innoviva, Inc. (NASDAQ:INVA) is one of the most promising stocks on our list.

TheFly reported on June 18 that INVA announced the launch of Nortiva Bio, a clinical-stage biopharmaceutical company focused on developing long-acting oral therapies through its proprietary LYNX drug delivery platform. The technology is designed to convert traditional daily oral medicines into extended-release treatments with potential dosing intervals of up to one month.

Nortiva aims to improve treatment effectiveness, safety, medication adherence, and patient experiences across multiple therapeutic areas. The company operates as a wholly owned subsidiary of INVA following the acquisition of the LYNX platform from Lyndra Therapeutics in 2025.

Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform

Separately, on June 16, Innoviva, Inc. (NASDAQ:INVA) Specialty Therapeutics, a subsidiary of INVA, announced an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories for XACDURO in selected international markets. Under the agreement, Dr. Reddy’s will oversee development, regulatory processes, and commercialization efforts across South and Central America, the Caribbean, Russia, and the Commonwealth of Independent States countries.

Innoviva Specialty Therapeutics will maintain rights to XACDURO in markets outside the licensed regions. The company is also eligible to receive upfront payments, milestone-based payments tied to regulatory and commercial progress, and royalties from sales generated within the covered territories.

Innoviva, Inc. (NASDAQ:INVA) is a biopharmaceutical company focused on critical care and infectious disease treatments, supported by stable revenue from its respiratory royalty portfolio and investments in innovative therapies.

While we acknowledge the risk and potential of INVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INVA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1